文献速递胰腺与胆道疾病消化内镜

ASGE高危标准在疑似胆总管结石患者评估中的准确性

Accuracy of ASGE high-risk criteria in evaluation of patients with suspected common bile duct stones.
PubMed 文献 · Gastrointest Endosc · 2017-02-04

本研究在2724例疑似胆总管结石住院患者中评估ASGE高危标准的准确性,1171例(43%)符合高危标准,确诊胆总管结石1076例(40%)。ASGE高危标准的特异性为74%,阳性预测值为64%;更严格标准(超声见胆总管结石、胆红素>4 mg/dL伴胆总管扩张)将特异性提高至94%、阳性预测值提高至85%。

要点

  • ASGE高危标准筛选疑似胆总管结石的阳性预测值为64%,超过三分之一患者接受诊断性ERCP。
  • 更严格标准(超声见结石、胆红素>4 mg/dL伴胆总管扩张)特异性94%、阳性预测值85%。
  • 第二次检测胆红素翻倍至>4 mg/dL或≥1.8 mg/dL特异性高但阳性预测值较低。

核心结论

  • ASGE高危标准虽显示患者胆总管结石概率>50%,但超过三分之一患者将接受诊断性ERCP;超声见胆总管结石和/或胆红素>4 mg/dL伴胆总管扩张的标准具有更高特异性和阳性预测值。

研究设计与样本

  • 连续纳入邵逸夫医院住院的疑似胆总管结石患者,均接受生化检测、腹部超声及胆总管结石确诊检查(MRCP、EUS、ERCP、术中胆管造影和/或胆总管探查)。

主要发现

  • 2724例疑似胆总管结石患者中,1171例(43%)符合ASGE高危标准。
  • 确诊检查(MRCP 2442例[90%]、EUS 67例[2%]、ERCP 659例[24%]、术中胆管造影229例[8%]、胆总管探查447例[16%])发现1076例(40%)胆总管结石。
  • ASGE高危标准的特异性为74%(95%CI 72%-77%),阳性预测值为64%(95%CI 61%-67%)。
  • 更严格标准(超声见胆总管结石、胆红素>4 mg/dL伴胆总管扩张)特异性94%(95%CI 93%-95%),阳性预测值85%(95%CI 82%-88%)。
  • 第二次检测胆红素翻倍至>4 mg/dL和≥1.8 mg/dL的特异性分别为98%(95%CI 96%-99%)和95%(95%CI 93%-96%),阳性预测值分别为62%(95%CI 48%-76%)和54%(95%CI 44%-65%)。

关键数值与推荐

  • ASGE高危标准:超声见胆总管结石,或胆红素>4 mg/dL(正常值<1.2 mg/dL),或胆红素≥1.8 mg/dL伴胆总管扩张和/或临床胆管炎。
  • 更严格标准:超声见胆总管结石、胆红素>4 mg/dL伴胆总管扩张。
  • 第二次检测胆红素翻倍至>4 mg/dL或≥1.8 mg/dL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: ERCP is recommended for patients considered high risk for choledocholithiasis after biochemical testing and abdominal US. Our aim was to determine whether the American Society for Gastrointestinal Endoscopy (ASGE) guidelines accurately select patients for whom the risk of ERCP is justified. METHODS: Consecutive patients hospitalized with suspected choledocholithiasis at Sir Run Run Shaw Hospital who received biochemical testing, abdominal US, and definitive testing for choledocholithiasis (MRCP, EUS, ERCP, intraoperative cholangiogram, and/or common bile duct [CBD] exploration) were identified. Patients with choledocholithiasis on abdominal US, with bilirubin levels >4 mg/dL (normal values <1.2 mg/dL), bilirubin levels ≥1.8 mg/dL plus a dilated CBD and/or clinical cholangitis were considered high risk per ASGE guidelines. RESULTS: Of 2724 patients with suspected choledocholithiasis, 1171 (43%) met high-risk criteria. Definitive testing (MRCP in 2442 [90%], EUS in 67 [2%], ERCP in 659 [24%], intraoperative cholangiogram in 229 [8%], and CBD exploration in 447 [16%]) revealed choledocholithiasis in 1076 [40%] patients. The specificity of the ASGE high-risk criteria was 74% (95% confidence interval [CI], 72%-77%) and positive predictive value was 64% (95% CI, 61%-67%). Using a more restrictive criteria (choledocholithiasis on abdominal US, bilirubin >4 mg/dL plus dilated CBD) improved the specificity to 94% (95% CI, 93%-95%) and positive predictive value to 85% (95% CI, 82%-88%). Doubling or more of bilirubin to >4 mg/dL and ≥1.8 mg/dL at second testing had specificities of 98% (95% CI, 96%-99%) and 95% (95% CI, 93%-96%), with positive predictive values of 62% (95% CI, 48%-76%) and 54% (95% CI, 44%-65%), respectively. CONCLUSIONS: Although ASGE high-risk criteria demonstrated >50% probability of the patient having choledocholithiasis, more than a third of the patients would receive diagnostic ERCPs. Criteria with choledocholithiasis on abdominal US and/or bilirubin levels >4 mg/dL plus a dilated CBD showed higher specificity and positive predictive value.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. He H, Tan C, Wu J, et al. Accuracy of ASGE high-risk criteria in evaluation of patients with suspected common bile duct stones. Gastrointest Endosc. 2017. PMID: 28174126. doi:10.1016/j.gie.2017.01.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。